Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 17

Results For "Type-2"

207 News Found

Roche and Fitterfly co-create 90-day diabetes programme
Startup | April 26, 2022

Roche and Fitterfly co-create 90-day diabetes programme

Designed to give instant insights on blood sugar, in-depth nutrition and wellness, this programme provides fitness assessments, personalisation and reports for doctors


Glenmark is the first to launch Teneligliptin and Pioglitazone Fixed-Dose Combination
News | April 25, 2022

Glenmark is the first to launch Teneligliptin and Pioglitazone Fixed-Dose Combination

The innovative Fixed-Dose Combination will help improving the glycemic control among adult patients with insulin resistance, those whose diabetes is uncontrolled by metformin; and also those who require addition of Teneliglitptin and Pioglitazone as separate drugs.


Study reveals over 80 % newly diagnosed diabetic patients have at least one cholesterol abnormality
News | April 08, 2022

Study reveals over 80 % newly diagnosed diabetic patients have at least one cholesterol abnormality

The findings support the fact that further extension of nationwide cardiovascular disease (CVD) risk identification programs and prevention strategies to reduce the occurrence of cardiovascular diseases are warranted


Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Biotech | April 05, 2022

Good business performance gives Boehringer Ingelheim tailwind for investment in R&D

R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)


Dupixent is a star in Sanofi’s immunology strategy
Biotech | March 29, 2022

Dupixent is a star in Sanofi’s immunology strategy

Dupixent peak sales ambition raised to more than €13 billion


Phase 3 data show Dupixent improves signs and symptoms of prurigo nodularis
Biotech | March 27, 2022

Phase 3 data show Dupixent improves signs and symptoms of prurigo nodularis

There are currently no approved systemic treatments for prurigo nodularis; regulatory filings for prurigo nodularis planned in the first half of 2022


Roche to present data across neuroscience portfolio at 2022 AAN Annual Meeting
News | March 25, 2022

Roche to present data across neuroscience portfolio at 2022 AAN Annual Meeting

Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment


Zolgensma used pre-symptomatically enables kids to stand and walk
Biotech | March 14, 2022

Zolgensma used pre-symptomatically enables kids to stand and walk

Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection


Daewoong  completes combination therapy of antidiabetic drug Enavogliflozin
News | February 27, 2022

Daewoong completes combination therapy of antidiabetic drug Enavogliflozin

Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy


Jardiance approved to treat adults with heart failure regardless of left ventricular ejection fraction
Drug Approval | February 25, 2022

Jardiance approved to treat adults with heart failure regardless of left ventricular ejection fraction

Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death or hospitalization for heart failure, regardless of ejection fraction